Mesoblast (MEOBF) Cash from Financing Activities (2014 - 2023)
Mesoblast's (MEOBF) quarterly Cash from Financing Activities came in at $38.8 million in Q2 2023, up 1848.96% year-over-year from $2.0 million in Q2 2022, and up 1625.27% quarter-over-quarter from -$2.5 million in Q1 2023.
Analysis
Mesoblast (MEOBF) Cash from Financing Activities (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Cash from Financing Activities across 10 years of filings, most recently posting $38.8 million for Q2 2023.
- In Q2 2023, Cash from Financing Activities rose 1848.96% year-over-year to $38.8 million; the TTM figure through Jun 2023 stood at $74.5 million (up 854.83% YoY), while the FY2026 annual figure was -$15.3 million, down 110.4% from the prior year.
- Cash from Financing Activities came in at $38.8 million for Q2 2023 at Mesoblast, up from -$2.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $106.4 million in Q1 2021 to a low of -$2.9 million in Q4 2021.
- Average Cash from Financing Activities over 5 years is $17.8 million, with a median of -$390000.0 recorded in 2019.
- Year-over-year, Cash from Financing Activities jumped 18272.22% in 2020 and slumped 294.22% in 2021.
- Over 5 years, Cash from Financing Activities stood at $48.2 million in 2019, then sank by 101.54% to -$744000.0 in 2020, then tumbled by 294.22% to -$2.9 million in 2021, then surged by 31.4% to -$2.0 million in 2022, then jumped by 2026.29% to $38.8 million in 2023.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $38.8 million in Q2 2023, -$2.5 million in Q1 2023, and -$2.0 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 15.05 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 7.18 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 49.29 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 167.70 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 249.12 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 7.52 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -33,000.00 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.69 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 38.76 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Dec 31, 2022 | -2.01 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Jun 30, 2022 | -2.22 Mn |
| Mar 31, 2022 | -2.57 Mn |
| Dec 31, 2021 | -2.93 Mn |
| Sep 30, 2021 | -2.15 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Mar 31, 2021 | 106.36 Mn |
| Dec 31, 2020 | -744,000.00 |
| Sep 30, 2020 | 6.54 Mn |
| Mar 31, 2020 | 48.13 Mn |
| Dec 31, 2019 | 48.19 Mn |
| Sep 30, 2019 | -36,000.00 |
| Mar 31, 2019 | 14.59 Mn |
| Dec 31, 2018 | 57.09 Mn |
| Sep 30, 2018 | 37.11 Mn |
| Jun 30, 2018 | -1.01 Mn |
| Mar 31, 2018 | 31.70 Mn |